Altimmune Inc. has reported encouraging results from a mid-stage trial of its experimental weight-loss drug, which showed a significant reduction in fat with minimal loss of muscle mass. This development addresses a key challenge faced by obesity drugmakers, as maintaining muscle mass while losing weight is crucial for overall health and well-being.
In the trial, more than 74% of the weight loss experienced by patients came from fat tissue, with only 25.5% attributed to lean mass. These results are comparable to those typically achieved through diet and exercise programs, highlighting the drug's potential as an effective treatment option for obesity.
The company's focus on minimizing muscle decline during weight loss could set a new standard in the development of obesity medications, offering hope for patients seeking safer and more effective treatment options.
